Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 4Lymphoma, B-Cell 3Lymphoma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1Disease Progression 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 328Methotrexate 182Cytarabine 164fludarabine phosphate 151Vincristine 128Dexamethasone 126fludarabine 123Peripheral Blood Stem Cell Transplantation 116Whole-Body Irradiation 108Etoposide 106Mycophenolic Acid 105Tacrolimus 95Busulfan 95Filgrastim 93Melphalan 81Cyclosporine 80Rituximab 79Doxorubicin 79Mercaptopurine 70Radiotherapy 62Antilymphocyte Serum 62Prednisone 57Granulocyte Colony-Stimulating Factor 57blinatumomab 55pegaspargase 54Asparaginase 54Thiotepa 52Daunorubicin 52Calcium Dobesilate 47Clofarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × axicabtagene ciloleucel × Clear all
NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡